To prospectively evaluate the primary causes for the use of mechanical ventilation in near-term neonates and to determine the rates of death, chronic lung disease, and neurological complications in these infants.
INTRODUCTION
Several large databases of information are available for the shortand long-term outcomes of prematurely born neonates [1] [2] [3] and previous investigations have evaluated the perinatal and neonatal factors associated with poor outcomes. [1] [2] [3] [4] [5] [6] In contrast, there is only limited data on the outcomes of neonates who are born Z34 weeks' estimated gestational age and are admitted to the neonatal intensive care unit for respiratory support. 7, 8 A recent estimate suggests that 17,000 such patients are admitted to neonatal intensive care units each year and that these represent almost a third of ventilated patients. 9 Mortality in these patients is estimated to be 9%, 9 although reasons for this high mortality rate are not clear. In addition, there is little information about morbidity among these infants. Most studies focus on neonates treated with extracorporeal membrane oxygenation or inhaled nitric oxide. [9] [10] [11] The purpose of our study was to evaluate the demographic characteristics of neonates Z34 weeks' estimated gestational age who were admitted to a neonatal intensive care unit and required assisted ventilation. Our goals in studying term and near-term neonates were to get a better estimate of the magnitude of abnormal outcomes and the proportion of these infants exposed to specific therapeutic interventions.
METHODS

Outcome Measures
In this prospective collection of data, our primary objective was to determine the occurrence of death, chronic lung disease (defined as the patient receiving supplemental oxygen >0.21 at 30 days of life), and neurologic complications (defined as prolonged seizures despite treatment, abnormal electroencephalogram read by a pediatric neurologist as showing seizures, or brain imaging showing brain atrophy, intracranial hemorrhage, or stroke). Our secondary objectives were to define the use of specific adjunctive therapies (volume expansion, surfactant, pressor support, highfrequency ventilation, inhaled nitric oxide, neuromuscular blockade, chemical or ventilatory alkalosis, and extracorporeal membrane oxygenation) by their frequency and timing, and to evaluate factors associated with poor outcomes (death, chronic lung disease, and neurological complications).
Patient Population
Neonates were eligible for enrollment if they (a) were Z34 completed weeks' estimated gestational age, (b) required endotracheal intubation for respiratory support during the first 72 hours of life, and were expected to continue on support for more than 6 hours, and (c) were provided care from birth to 72 hours by a single health-care team. The gestational age assignment was based on the best obstetrical estimate before delivery and was recorded as completed weeks. Outborn neonates were enrolled only if their care was provided from birth by the health-care team reporting the data. That is, outborn infants were enrolled by site investigators when the health-care team at the ''referred to'' hospital managed the care from the infant's birth. In some cases, these patients were being cared for at satellite sites that were staffed by neonatologists from regional referral centers who were participating in the study. In other cases, the transport team from the referring hospital was present at the births of the infants. This was performed to insure that data on the timing of each new therapy could be assessed.
Study Administration
This study was approved by the institutional review board at each institution. Data were collected from each site using a Web-based case report form. Each data entry field on the form had preprogrammed value boundaries that decreased the chance of data entry errors. A case report form could not be finalized until all required fields were completed. Site visits were conducted to monitor the accuracy of data collection and the adherence of sites to good clinical practice. Of the case report forms, 70% were checked against the source document (medical record). Data accuracy was greater than 97%. Data discrepancies generated a query resolution process, which resulted in the data error being fixed. Once all query resolutions were completed, the database was closed.
Statistics
The primary goal of this study was to provide descriptive statistics of the patient population and their outcomes. Secondarily, we used logistic regression to analyze the discrete outcomes (lived/died, chronic lung disease F yes/no, and neurological morbidity F yes/no). A stepwise regression analysis was used initially to determine significant independent variables associated with an increased risk for each outcome (0.05 p-value for model entry, 0.10 p-value for model exit). Estimated gestational age, 5-minute Apgar, mode of delivery, gender, inborn vs outborn, presence of a major anomaly, primary diagnosis, and each of the treatments were included in our analysis. The independent variables found to be significant in the stepwise procedure were then investigated further to develop a final model for each outcome variable. We evaluated adjusted odds ratios for all factors retained in the logistic regression model.
RESULTS
Patient Population
In this prospectively collected cohort (n ¼ 1011), the mean estimated gestational age was 37±2 weeks and the birth weight was 2.9±0.6 kg. The majority of neonates were male (62%), white (69%), delivered by cesarean section (55%), and born at the hospital of care (''inborn'', 69%) ( Table 1) . Of the cesarean sections, 40% were performed electively and the average age of the patients' mothers was 28±6 years. A total of 304 obstetrical complications were reported in 262 (26%) neonates, with the most common being gestational diabetes (n ¼ 91, 34%), oligohydramnios (n ¼ 58, 22%), polyhydramnios (n ¼ 35, 13%), placental abruption (n ¼ 25, 9%), chorioamnionitis (n ¼ 22, 8%), prenatal diagnosis of congenital diaphragmatic hernia (n ¼ 18, 7%), pre-eclampsia (n ¼ 15, 6%), lack of prenatal care (n ¼ 10, 4%), and hydrops (n ¼ 8, 3%). Fetal distress was reported in 348 (34%) neonates.
Primary Diagnoses Leading to the Use of Assisted Ventilation Respiratory distress syndrome (n ¼ 437, 43%) was the most common pulmonary illness. Other pulmonary diagnoses included meconium aspiration syndrome (n ¼ 98, 9.7%), pneumonia/sepsis (n ¼ 84, 8.3%), transient tachypnea of the newborn (n ¼ 40, 3.9%), idiopathic persistent pulmonary hypertension (n ¼ 32, 3.2%), aspiration of blood or amniotic fluid (n ¼ 24, 2.3%), and lung hypoplasia not related to congenital diaphragmatic hernia (n ¼ 14, 1.4%). The primary reason for support in the remaining 282 patients was a major congenital anomaly (n ¼ 172, 17%); profound hypoxic-ischemic encephalopathy (n ¼ 31, 3.1%); and surgical support (n ¼ 21, 2.1%); and in 58 (5.7%) patients, a primary cause for the need for assisted ventilation was not definable.
Major congenital anomalies were present in 209 (21%) patients. The most commonly reported anomalies were gastroschisis (n ¼ 52, 25%), congenital diaphragmatic hernia (n ¼ 31, 15%), tracheoesophageal fistula (n ¼ 13, 6%), transposition of the great arteries (n ¼ 12, 6%), myelomeningocele (n ¼ 11, 5%), omphalocele (n ¼ 9, 4%), and trisomy 21 (n ¼ 8, 4%).
Reported Use of Adjunctive Therapies
Of the 1011 ventilated patients, 864 (85%) received at least one adjunctive therapy (extra volume, surfactant, vasopressors, highfrequency ventilation, inhaled nitric oxide, neuromuscular blockade, alkalosis, or extracorporeal membrane oxygenation), 521 (52%) received at least two of these therapies, and 304 (30%) received at least three of these therapies. The median number of different therapies was 2 (25 to 75 percentile ¼ 1 to 3).
Surfactant was used in 558 (55%) patients, vasopressors in 353 (35%), high-frequency ventilation in 206 (20%), inhaled nitric oxide in 172 (17%), neuromuscular blockade in 167 (17%), alkalosis in 37 (3.6%), and extracorporeal membrane oxygenation in 36 (3.6%). During the first 48 hours, 608 (60%) patients were given extra volume. The most commonly used volume resuscitations were normal saline (n ¼ 500, 82%), albumin (n ¼ 67, 11%), and blood products (n ¼ 37, 6%). The median amount of extra volume given over the first 48 hours after birth was 25 cm 3 /kg (25 to 75 percentile ¼ 10 to 53 cm 3 /kg). Alkalosis was achieved by hyperventilation in 21 patients, infusion of bicarbonate in 10 patients, and use of both of these therapies in six patients. In patients treated with alkalosis, the median maximum pH value was 7.58 (25 to 75 percentile ¼ 7.53 to 7.61) and the median lowest PaCO 2 value was 22 (25 to 75 percentile ¼ 19 to 25).
The timing of therapies showed that surfactant was used as early (median age 8.4 hours, 25 to 75 percentile ¼ 3.8 to 24.2 hours) therapy, primarily in neonates with respiratory distress syndrome (70% of surfactant use was in neonates with respiratory distress syndrome), and extracorporeal membrane oxygenation was used later (median age 26.9 hours, 25 to 75 percentile ¼ 14.9 to 40.8 hours), primarily in neonates with congenital diaphragmatic hernia (44% of extracorporeal membrane oxygenation use was in neonates with congenital diaphragmatic hernia) (Figure 1 ).
Patients Who Met Criteria for Treatment with Extracorporeal Membrane Oxygenation
In all, 73 (7%) patients met criteria for treatment with extracorporeal membrane oxygenation, but only 36 of 73 (49%) were treated with this therapy. The median duration of treatment was 6 days (25 to 75 percentile ¼ 4 to 11 days). In patients who met extracorporeal membrane oxygenation criteria, inhaled nitric oxide was the most commonly reported rescue treatment, but most (91%) patients had received at least two other therapies before inhaled nitric oxide was tried. The median number of reported treatments before extracorporeal membrane oxygenation was 5 (25 to 75 percentile ¼ 4 to 6). Of the 36 patients treated with extracorporeal membrane oxygenation, 16 (44%) had congenital diaphragmatic hernia or severe lung hypoplasia. In the 37 patients who met criteria for treatment with ECMO but were not treated with ECMO, 33 (89%) survived, 15 (41%) developed chronic lung disease, and two (5%) had brain injury.
A total of 14 patients who met extracorporeal membrane oxygenation criteria and were treated with it died despite receiving the therapy; 10 of these 14 had major anomalies (nine F congenital diaphragmatic hernia, one with coarctation of the aorta). Four patients who met the criteria and were considered for this therapy died without receiving it F one patient died before transport and three died before the therapy could be established. These four patients are not included in the extracorporeal membrane oxygenation statistics.
Outcomes Mortality. A total of 51 (5%) patients died. The most commonly reported causes of death were major congenital anomalies (n ¼ 23, 45%) and progressive respiratory failure (n ¼ 11, 21%). In eight (15%) patients, intensive care was withdrawn. Of the 51 neonates who died 40 (78%) had major anomalies (12 F congenital diaphragmatic hernia, nine F heart anomalies, eight F brain anomalies, six F major chromosomal anomalies, and five with other anomalies).
Of the 51 patients who died, 33 did not meet the criteria for, and consequently were not treated with, extracorporeal membrane oxygenation. A total of 14 patients died despite treatment with extracorporeal membrane oxygenation; and four patients, who met the criteria for extracorporeal membrane oxygenation died without being treated (one patient died before transport and three died before the therapy could be established).
Morbidity. Chronic lung disease was diagnosed in 109 (11%).
Median time of ventilator support for survivors was 3 days (25 to 75 percentile ¼ 1 to 5 days); in nonsurvivors, it was 5 days (25 to 75 percentile ¼ 3 to 15 days). Median age at discharge in patients who survived was 13 days (25 to 75 percentile ¼ 9 to 21 days); for nonsurvivors, it was 7 days (25 to 75 percentile ¼ 2 to 27 days).
In all, 86 patients (9%) had a report of a neurological complication. A total of 35 (41%) of the 86 neonates had intraventricular hemorrhage reported (grades 1 to 2, n ¼ 29; grades 3 to 4, n ¼ 6), 30 (35%) neonates had prolonged seizures (despite treatment) and a clinical history of hypoxic-ischemic encephalopathy, six (7%) were reported to be comatose, four (5%) had brain atrophy, two (2%) developed areas of cerebral infarct, two (2%) were labeled as brain dead, and seven (8%) had other forms of brain injury (as evidenced by abnormal computed tomography or magnetic resonance imaging), but no history to suggest a cause or primary diagnosis.
Risk factors for adverse events (Table 1) . In univariate and multivariate analyses, the most important risk factor associated with either death or chronic lung disease was the presence of a major anomaly. Compared with neonates without anomalies (n ¼ 802), neonates with major anomalies (n ¼ 209) were more likely to die (1.4%. no anomaly vs 19% anomaly present) and to develop chronic lung disease (9% no anomaly vs 18% anomaly present). Adverse neurological events occurred at a similar rate in neonates with and without major anomalies (9% no anomaly vs 8% anomaly present). In patients with no diagnosis of hypoxicischemic encephalopathy or major neurological anomaly, the rate of neurological adverse events was 6% (56/969), which was significantly lower than the neurological event rate for neonates in whom ventilation was initiated due to hypoxic-ischemic encephalopathy (24/31, 77%).
In patients who had blood gas data on days 1 (20 to 28 hours), 2 (44 to 52 hours), and 3 (68 to 76 hours), we found that the oxygenation index was significantly higher on days 1, 2, and 3 in patients treated with inhaled nitric oxide and in neonates who died or were treated with extracorporeal membrane oxygenation ( Figure 2) . Similarly, neonates who developed chronic lung disease had higher oxygenation indexes on days 1 and 2 ( Figure 3 ). There were no differences in pH or PaCO 2 between these groups. There Oxygenation index (median on days 1 (20 to 28 hours after birth), 2 (44 to 52 hours after birth), and 3 (68 to 76 hours after birth)) for neonates who survived and were not treated with extracorporeal membrane oxygenation (white bars); for neonates who were treated with inhaled nitric oxide (gray bars); and for neonates who died or were treated with extracorporeal membrane oxygenation (black bars) (*p<0.05 compared with the neonates who survived without extracorporeal membrane oxygenation).
were no differences in oxygenation, pH, PaCO 2 , or ventilator settings for neonates with adverse neurological events (data not shown).
In multivariate logistic regression, the factors we found to be associated with an increased risk of death were the presence of a major anomaly (adjusted odds ratio ¼ 23, confidence interval ¼ 11 to 54, p<0.001); an Apgar score less than 5 at 5 minutes (adjusted odds ratio ¼ 6.4, confidence interval ¼ 2.5 to 16, p<0.001); treatment with extracorporeal membrane oxygenation (adjusted odds ratio ¼ 5.9, confidence interval ¼ 2 to 18, p ¼ 0.001); and treatment with inhaled nitric oxide (adjusted odds ratio ¼ 2.5, confidence interval ¼ 1.0 to 5.6, p ¼ 0.04).
The factors that we found to be associated with an increased risk of chronic lung disease were the diagnosis of lung hypoplasia (adjusted odds ratio ¼ 4.2, confidence interval ¼ 1.7 to 10.2, p ¼ 0.002), most often due to diaphragmatic hernia; the presence of a major anomaly (adjusted odds ratio ¼ 3. The factors that we found to be associated with an increased risk of adverse neurological events were the presence of a major neurological anomaly or a primary diagnosis of hypoxic-ischemic encephalopathy (adjusted odds ratio ¼ 18. 
DISCUSSION
We describe a large prospectively collected experience of neonates who were Z34 weeks' estimated gestational age, admitted to the neonatal intensive care unit, and required assisted ventilation. Our study demonstrates the diversity of illness that leads to the use of assisted ventilation in term and near-term neonates. Based on previous reports, 10, 12, 13 we were surprised at the number of term and near-term neonates with respiratory distress syndrome, representing 43% of our total sample. Several studies involving treatment with extracorporeal membrane oxygenation and inhaled nitric oxide suggest that meconium aspiration syndrome is the leading cause of severe respiratory failure, not respiratory distress syndrome, in term and near-term neonates. 12,14 -16 In designing therapeutic strategies to improve the outcome of term and nearterm neonates with severe respiratory failure, it is important to recognize this diversity.
We also describe the degree to which near-term neonates who are placed on assisted ventilation are treated with other therapies. Most (52%) infants received at least two adjunctive therapies. Knowing the frequency and timing of specific treatments and how those treatments might influence patient outcomes is essential to planning and conducting any clinical trial. Recently, several studies have stopped prior to completion due to confounding use of ''unproven'' therapies and drug-drug interactions that were not anticipated. [17] [18] [19] In exploring our observations, we identified three potential selection biases that influence care delivery: relative use, timing of delivery, and diagnosis driving the use of a therapy. For example, surfactant was used commonly, early, and mainly in neonates with respiratory distress syndrome. Extracorporeal membrane oxygenation was used rarely, late, and primarily in neonates with congenital diaphragmatic hernia. Understanding each of these selection biases is important for any retrospective review of the data.
In a logistic model, there is an assumption that each patient is equally likely to be exposed to a specific therapy. In our data set, it is clear that this was not the case. Therapies are used in different ways for different diseases and at different times. Therefore, besides the clear associations between major anomalies and poor outcomes, most of our observations have been driven by selection bias, severity of disease, and timing and do not represent cause and effect.
This does not mean that the adjusted odds ratios are not valuable. The true value of these odds ratios is that they provide us with a sense of risk associated with progression to the next level of care (if there was some sense of a threshold or an indication for the next therapy that was consistent from site to site and baby to baby, a different model might be able to be built). Neonates who are judged to be in need of inhaled nitric oxide or extracorporeal membrane oxygenation are at increased risk for mortality and morbidity. Knowing that this risk exists may increase the likelihood of transport to higher levels of care. Patients in this study were at significant risk for mortality, pulmonary morbidity, and adverse neurological events, all of which occurred at rates similar to those reported for neonates being referred for higher levels of care. 10, 20 Much of the mortality and morbidity was in neonates who had major congenital anomalies or a history to suggest significant hypoxic-ischemic injury.
We found very little ''hidden'' 21 mortality. There were four patients who were considered to be extracorporeal membrane oxygenation candidates in whom this therapy could not be established. All four died. This is similar to the data presented in a recent trial by Konduri in which a total of ''4 infants on iNO had rapid deterioration and died before ECMO could be initiated. '' 22 While this represents only 0.4% of our study population and 1% of theirs, it reminds us that neonates who benefit from extracorporeal membrane oxygenation can die before it can be offered. We were unable to confirm previous observations suggesting that alkalosis or paralysis were associated with worse outcomes. 23 In summary, we report on the treatment and outcome of ventilated term and near-term neonates. Our data suggest that these infants are at significant risk for death, chronic lung disease, and neurological complications. In addition to assisted ventilation, they are commonly treated with multiple interventions, some of which are associated with increased odds of morbidity and mortality. Our data should be helpful in planning future trials that are designed to improve the health outcomes of these neonates.
